Compare Adaptive Biotechnologies Corp (ADPT) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs State Street SPDR S&P Homebuilders ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while State Street SPDR S&P Homebuilders ETF trades at $106.45. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | XHB | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $121.36 |
52-Week Low | $10.24 | $94.86 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
XHB (SPDR S&P Homebuilders ETF) trades at $111.29, down 1.13% amid mixed housing data. Technical indicators show a bullish bias with strong moving average support, while oscillators remain neutral. Recent news highlights declining new home sales but improving builder sentiment, creating a complex backdrop for the homebuilding sector.
The ETF faces headwinds from higher mortgage rates and construction costs, but potential exists if housing demand recovers. Key risks include interest rate sensitivity and economic uncertainty, while technical support near $108 provides a cushion for near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
